Shots:

• The P-III EMPLULSE study (NCT04157751) will evaluate clinical benefits safety and tolerability of Jardiance (empagliflozin- 10mg- PO) in ~500 patients hospitalized for acute heart failure who have been stabilized including patients both with and without T2D
• The P-III EMPULSE study will evaluate whether Jardiance will able alleviate symptoms associated with HF and improve outcomes after discharge from the hospital with 1EPs as net clinical benefit- a composite of all-cause mortality- number of heart failure events- time to first heart failure event and change from baseline in KCCQ-CSS
• Jardiance (empagliflozin- qd) is an oral therapy used to lower the blood sugar level in adults with T2D and cardiovascular diseases and is contraindicated in patients with T1D and diabetic ketoacidosis

Click here to­ read full press release/ article | Ref: Eli Lilly | Image: Livemint